Floatz Rating
C39/100
Confidence
Indicative
Sponsor
Umoja Biopharma
Modality
Small molecule
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06528301CT.gov A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · B-Cell Non-Hodgkin Lymphoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Sirolimus (this asset) | Umoja Biopharma | P1 | C · 39 |
| Vindesine | Children's Cancer Group, China | P4 | BBB |
| Anti-Cd20/Cd3 Monoclonal Antibody Regn1979 | University of Birmingham | P3 | BBB |
| cd19-ucart | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | P4 | BB |
| Lenalidomide | Shanghai Junshi Bioscience Co., Ltd. | P4 | BB |
| Zanubrutinib | The First Affiliated Hospital of Soochow University | P4 | BB |
| Cyclophosphamide | Swiss Cancer Institute | P4 | BB |
| Methotrexate | Children's Cancer Group, China | P4 | BB |
| Rituximab | Mwanasha Merrill, MD | P4 | BB |
+42 more in the B-Cell Non-Hodgkin Lymphoma cohort
Other indications for Sirolimus
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Tuberous Sclerosis | — | P3 | BB · 70 |
| Chronic Myeloid Leukemia | — | P3 | BB · 67 |
| Disease Related To Transplantation | — | P4 | BB · 66 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- VindesineChildren's Cancer Group, ChinaBBB
- Anti-Cd20/Cd3 Monoclonal Antibody Regn1979University of BirminghamBBB
- cd19-ucartUnion Hospital, Tongji Medical College, Huazhong University of Science and TechnologyBB
- LenalidomideShanghai Junshi Bioscience Co., Ltd.BB
- ZanubrutinibThe First Affiliated Hospital of Soochow UniversityBB
Citation
Floatz Terminal. Sirolimus in B-Cell Non-Hodgkin Lymphoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 14, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/sirolimus-b-cell-non-hodgkin-lymphoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →